Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000179 · ClinicalTrials.gov registry record · Phase 3
Agitation in Alzheimer's Disease
A Phase 3 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00000179 is a Phase 3 study that has completed, run by National Institute on Aging (NIA).
The verdict
NCT00000179, a Phase 3 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs for agitation in AD patients. Behavior management, a non drug approach, has been effective in reducing signs of agitation. Researchers have yet to compare the effectiveness of drug versus non drug therapy to treat agitation in AD patients and determine which is the best treatment. The Alzheimer's Disease Cooperative Study, with funding from the National Institute on Aging, is conducting an agitation treatment program at 21 sites in 16 States. This study will assess which of the above treatments is most effective.
Interventions
- DRUG Trazodone
- DRUG Haloperidol
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000179
The ClinicalTrials.gov registry entry for NCT00000179 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Aging (NIA), which has 131 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trazodone is the first listed.
NCT00000179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000179 about?
NCT00000179 is a clinical study titled "Agitation in Alzheimer's Disease". Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for patients at home very difficult. Trazodone and haldol are two of the most commonly prescribed drugs ...
What is the current status of trial NCT00000179?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00000179?
The interventions under investigation include: Trazodone (DRUG), Haloperidol (DRUG).
Who is sponsoring clinical trial NCT00000179?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.